Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod + Pembrolizumab in HNSCC
NCT04633278Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vidutolimod in head and neck squamous cell carcinoma (HNSCC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Confirmed Objective Response Rate at 109 weeks. Started Jan 2021; status: terminated.
02
Drugs
vidutolimod
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04633278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633278.